Esperion Therapeutics, Inc.
US ˙ NasdaqGM ˙ US29664W1053

SecurityESPR / Esperion Therapeutics, Inc.
InsiderKoenig Sheldon L.
This page shows the track record and history of Koenig Sheldon L. insider trades in Esperion Therapeutics, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Koenig Sheldon L. in ESPR / Esperion Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2023-05-09 20,000 1.2596 20,000 1.2596 25,192 332 3.2400 39,608 157.22
2022-08-05 8,606 5.8041 8,606 5.8041 49,950

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ESPR / Esperion Therapeutics, Inc. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Koenig Sheldon L. in ESPR / Esperion Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-09-17 28,427 2.7880 28,427 2.7880 79,254 0 2.7200 -1,933 -2.44
2025-06-17 30,474 1.1090 30,474 1.1090 33,796
2025-03-18 13,047 1.5040 13,047 1.5040 19,623
2024-12-17 12,447 2.4660 12,447 2.4660 30,694
2024-09-17 14,550 1.7960 14,550 1.7960 26,132
2023-03-17 6,999 1.7830 6,999 1.7830 12,479
2023-03-07 5,441 5.0560 5,441 5.0560 27,510
2022-09-19 3,394 6.9380 3,394 6.9380 23,548
2022-06-17 4,552 4.9910 4,552 4.9910 22,719
2022-03-17 571 4.5800 571 4.5800 2,615

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ESPR / Esperion Therapeutics, Inc. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2025-09-18 2025-09-17 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 2.7880 -28,427 -79 1,518,831
2025-06-18 2025-06-17 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 1.1090 -30,474 -34 1,541,488
2025-03-19 2025-03-18 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 1.5040 -13,047 -20 1,571,962
2025-03-17 2025-03-14 4 Koenig Sheldon L. ESPR Common Stock A - Award D 840,000 1,585,009
2024-12-18 2024-12-17 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 2.4660 -12,447 -31 739,819
2024-09-18 2024-09-17 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 1.7960 -14,550 -26 752,266
2024-03-15 2024-03-14 4 Koenig Sheldon L. ESPR Common Stock A - Award D 454,000 766,816
2023-05-10 2023-05-09 4 Koenig Sheldon L. ESPR Common Stock P - Purchase D 1.2596 20,000 25 312,816
2023-03-20 2023-03-17 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 1.7830 -6,999 -12 292,816
2023-03-15 2023-03-14 4 Koenig Sheldon L. ESPR Common Stock A - Award D 105,000 299,815
2023-03-08 2023-03-07 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 5.0560 -5,441 -28 194,815
2022-09-20 2022-09-19 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 6.9380 -3,394 -24 198,257
2022-08-08 2022-08-05 4 Koenig Sheldon L. ESPR Common Stock P - Purchase D 5.8041 8,606 50 198,771
2022-06-21 2022-06-17 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 4.9910 -4,552 -23 190,165
2022-03-18 2022-03-17 4 Koenig Sheldon L. ESPR Common Stock S - Sale D 4.5800 -571 -3 194,717
2022-03-16 2022-03-14 4 Koenig Sheldon L. ESPR Common Stock A - Award D 116,000 195,288
2021-11-01 2021-10-29 4 Koenig Sheldon L. ESPR Common Stock A - Award D 26,700 76,700
2021-05-18 2021-05-17 4 Koenig Sheldon L. ESPR Stock Option (right to buy) A - Award D 20.87 120,000 120,000
2021-05-18 2021-05-17 4 Koenig Sheldon L. ESPR Common Stock A - Award D 20,000 50,000
2021-01-29 2021-01-28 4 Koenig Sheldon L. ESPR Stock Option (right to buy) A - Award D 32.12 150,000 150,000
2021-01-29 2021-01-28 4 Koenig Sheldon L. ESPR Common Stock A - Award D 30,000 30,000
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)